CTI BioPharma

CTI was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. We strive to do business better than other biopharmaceutical companies. Better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. A willingness to push the limits to achieve challenging goals is the essential attribute that sets CTI employees apart.
Company Growth (employees)
Seattle, US
Size (employees)
100 (est)
CTI BioPharma was founded in 1992 and is headquartered in Seattle, US

CTI BioPharma Office Locations

CTI BioPharma has an office in Seattle
Seattle, US (HQ)
600 3101 Western Ave
Show all (1)

CTI BioPharma Financials and Metrics

CTI BioPharma Financials

CTI BioPharma's revenue was reported to be $57.4 m in FY, 2016

Revenue (Q2, 2017)

22.2 m

Net income (Q2, 2017)

5.4 m

EBIT (Q2, 2017)

5.3 m

Market capitalization (22-Dec-2017)

115.8 m

Cash (30-Jun-2017)

74.7 m


49.4 m
CTI BioPharma's current market capitalization is $115.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


34.7 m60.1 m16.1 m57.4 m

Revenue growth, %


Cost of goods sold

137 k895 k1.9 m1.4 m

Gross profit

34.5 m59.2 m14.2 m56 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


362 k1.4 m1.3 m39.5 m2.7 m1.1 m964 k36.5 m7.4 m4.4 m754 k22.2 m

R&D expense

7.2 m12.2 m14 m16.5 m17.5 m19.3 m18.4 m20.8 m16.7 m17.7 m9.3 m8.9 m

General and administrative expense

8.5 m16.8 m13.8 m12.6 m12.3 m12.6 m13.7 m11.3 m9.6 m15.2 m10.7 m8 m

Operating expense total

15.9 m29.1 m28 m32.1 m30.2 m32.1 m32.9 m32.3 m26.4 m33.1 m20.1 m17 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


71.6 m70.9 m128.2 m44 m

Accounts Receivable

235 k2 m282 k378 k


3.6 m3.4 m3.7 m1.5 m

Current Assets

80.5 m80.5 m135 m55.8 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


27.2 m50.6 m33.2 m29.9 m44.4 m54.9 m46.4 m104.6 m76.7 m61.6 m33.3 m74.7 m

Accounts Receivable

540 k503 k613 k1.2 m1.3 m880 k422 k666 k559 k620 k311 k480 k


3.7 m5 m5 m4.5 m3.6 m3.6 m2.6 m2.9 m2.6 m2.6 m1.5 m1.5 m

Current Assets

33.7 m59.9 m42.3 m55.9 m53.5 m63.9 m53.3 m113.9 m88.9 m67.9 m36.8 m78.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(43.6 m)(94.2 m)(120.8 m)(53 m)

Depreciation and Amortization

1.6 m1.1 m990 k831 k

Accounts Receivable

(227 k)(2 m)1.6 m(156 k)


4.5 m46 k(402 k)567 k
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(29 m)(27.4 m)(28.6 m)(32.6 m)(32.6 m)3.3 m(19.8 m)(29.2 m)(19.8 m)

Accounts Receivable

613 k1.2 m1.3 m880 k422 k666 k559 k620 k311 k


5 m4.5 m3.6 m3.6 m

Accounts Payable

6.4 m6.3 m10.3 m11.2 m13.4 m17.7 m14 m13.7 m11.9 m
Y, 2017


9.4 x

Financial Leverage

2.2 x
Show all financial metrics

CTI BioPharma Operating Metrics

FY, 2016

Phase III Trials

Show all operating metrics

CTI BioPharma Market Value History

CTI BioPharma's Web-traffic and Trends

CTI BioPharma Online and Social Media Presence

CTI BioPharma Company Life and Culture

You may also be interested in